Agent- and Dose-Specific Intestinal Obstruction Safety of GLP-1 Receptor Agonists and SGLT2 Inhibitors: A Network Meta-Analysis of Randomized Trials
I-Shou University · Chang Gung University · +16 more institutions
Abstract
Glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT2) inhibitors have reshaped pharmacological management of type 2 diabetes, but emerging safety signals suggest a possible association with intestinal obstruction. Because many candidates for these agents already harbor risk factors for ileus and bowel obstruction, clarifying agent- and dose-specific gastrointestinal safety is clinically important. We aimed to re-evaluate the risk of intestinal obstruction across individual GLP-1 receptor agonists and SGLT2 inhibitors, with particular attention to dose stratification. We systematically searched eight databases through 21 January 2025 to identify randomized controlled…
Citation impact
- FWCI
- 81.57
- Percentile
- 99%
- References
- 0
Authors
19- JCJiann-Jy ChenCorresponding
I-Shou University
- CHChih-Wei Hsu
Chang Gung University, Kaohsiung Chang Gung Memorial Hospital
- CHChao-Ming Hung
I-Shou University
- MSMein-Woei Suen
Asia University, China Medical University, China Medical University Hospital
- HWHung-Yu Wang
Kaohsiung Municipal Kai-Syuan Psychiatric Hospital
Topics & keywords
- Canagliflozin
- Odds ratio
- Placebo
- Randomized controlled trial
- Absolute risk reduction
- Number needed to harm
- Number needed to treat
- Relative risk
- Good health and well-being